Lung Bioavailability of CHF 1535 NEXThaler in Asthma

Phase 2, randomised, open-label trial of beclomethasone dipropionate and formoterol in asthma (6 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Formoterol Area Under the Curve from time 0 to last quantifiable concentration at 12 hours and Beclomethasone-17-monopropionate Area Under the Curve from time 0 to last quantifiable concentration at 12 hours. Started Nov 2012; status: completed.